MedTrace Logo

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

NCT00093093 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2012-06-22

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Viramidine

DRUG

Ribavirin

DRUG

pegylated interferon alfa-2a

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Ralph T. Doyle · Bausch Health Americas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • France
  • Israel
  • Italy
  • Poland
  • Puerto Rico
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00093093 on ClinicalTrials.gov